Targeting of the renin-angiotensin system by antisense gene therapy
Authors:
- Mohan K. RaizadaMRMohan K. Raizada
- Sharon C. FrancisSFSharon C. Francis
- Hongwei WangHWHongwei Wang
- Craig H. GelbandCGCraig H. Gelband
- Phyllis Y. ReavesPRPhyllis Y. Reaves
- Michael J. KatovichMKMichael J. Katovich
- 1 April 2000
- journal article
- review article
- Published by Wolters Kluwer Health in Journal Of Hypertension
- Vol. 18 (4) , 355-362
Abstract
Traditional pharmacological agents have been successfully used for the treatment of hypertension for a number of decades. However, this therapeutic regimen has reached a conceptual plateau and a cure for the disease is far from appearing on the horizon. With this in mind, and recent advances in state of the art gene delivery system coupled with the anticipated completion of the human genome project, it is timely to think about the possibility of treating and/or curing hypertension using genetic means. In this review, we discuss the role of renin-angiotensin system (RAS) in hypertension; the current gene delivery/gene transfer systems and the RAS as a target for gene therapy to treat hypertension; the successful use of retroviral vectors to deliver antisense to the AT1 receptor (AT1-AS) to prevent the development of hypertension and cardiovascular pathophysiology; the potential use of the viral vectors for the reversal of hypertension; and the future of antisense gene therapy and potential advantages and limitations of this regimen in the treatment and/or control of hypertension.Keywords
This publication has 35 references indexed in Scilit:
- Inducible long-term gene expression in brain with adeno-associated virus gene transferGene Therapy, 1998
- Adenovirus-mediated kallikrein gene delivery reverses salt-induced renal injury in Dahl salt-sensitive ratsKidney International, 1998
- Human Kallikrein Gene Delivery Attenuates Hypertension, Cardiac Hypertrophy, and Renal Injury in Dahl Salt-Sensitive RatsHuman Gene Therapy, 1998
- Losartan Versus Gene TherapyHypertension, 1997
- Prolonged Reduction of High Blood Pressure With an In Vivo, Nonpathogenic, Adeno-Associated Viral Vector Delivery of AT 1 -R mRNA AntisenseHypertension, 1997
- ACE Inhibition, Endothelial Function and Coronary Artery LesionsDrugs, 1997
- Human Atrial Natriuretic Peptide Gene Delivery Reduces Blood Pressure in Hypertensive RatsHypertension, 1995
- MOLECULAR MECHANISMS OF VASCULAR HYPERTROPHY IN THE SPONTANEOUSLY HYPERTENSIVE RATClinical and Experimental Pharmacology and Physiology, 1995
- Transient Decrease in High Blood Pressure by In Vivo Transfer of Antisense Oligodeoxynucleotides Against Rat AngiotensinogenHypertension, 1995
- Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis.Journal of Clinical Investigation, 1995